Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.

ABSTRACT:

Introduction

In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m² in the avacopan group and 4.1 ml/min per 1.73 m² in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR ≤20 ml/min per 1.73 m².

Methods

eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups.

Results

In ADVOCATE, 27 of 166 patients (16%) in the avacop

SUBMITTER: Cortazar FB 

PROVIDER: S-EPMC10105055 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature